Guided Therapeutics (GTHP) EPS (Diluted) Growth (3y) (2018 - 2025)
Guided Therapeutics (GTHP) EPS (Diluted) Growth (3y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.81 Bn | 175.52 Bn | 6.27 Bn | -6.43% |
| 2 | Stryker | 128.98 Bn | 126.10 Bn | 3.81 Bn | 7.66% |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | 3.09% |
| 4 | Boston Scientific | 68.36 Bn | 66.91 Bn | 3.61 Bn | 62.91% |
| 5 | Edwards Lifesciences | 47.70 Bn | 44.03 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.67 Bn | 27.55 Bn | 750.30 Mn | 63.42% |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 30.57% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | 35.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.61% |
| Sep 30, 2025 | 31.78% |
| Jun 30, 2025 | 34.27% |
| Mar 31, 2025 | 48.97% |
| Dec 31, 2024 | 31.54% |
| Sep 30, 2024 | -47.23% |
| Jun 30, 2024 | 46.27% |
| Mar 31, 2024 | 42.97% |
| Dec 31, 2023 | -25.99% |
| Sep 30, 2023 | -26.00% |
| Jun 30, 2023 | 96.19% |
| Mar 31, 2023 | -26.00% |
| Dec 31, 2022 | -26.00% |
| Sep 30, 2022 | 90.73% |
| Jun 30, 2022 | 96.38% |
| Mar 31, 2022 | 90.96% |
| Dec 31, 2021 | 90.34% |
| Sep 30, 2021 | 64.58% |
| Jun 30, 2021 | -27.16% |
| Mar 31, 2021 | -341.96% |